KMT2A and acute lymphoblastic leukemia: We confirmed a tumor-maintaining potency of the MLL-AF4 fusion protein in PDX models in vivo and used the technique to identify DDIT4L as therapeutic targets in PDX ALL carrying the recently described DUX4-IGH translocation.